Alzheimer's disease (AD) is heterogenous at the molecular level. Understanding this
heterogeneity is critical for AD drug development. Here we define AD molecular subtypes …

Alzheimer's disease (AD) is a neurodegenerative disease that primarily occurs in elderly
individuals with cognitive impairment. Although extracellular β-amyloid (Aβ) accumulation …

Alzheimer's disease (AD) is heterogenous on the molecular level. Understanding this
heterogeneity is critical for AD drug development. We aimed to define AD molecular …

The pathogenesis of Alzheimer's disease (AD) is believed to involve the accumulation of
amyloid-β in the brain, which is produced by the sequential cleavage of amyloid precursor …

Non-familial Alzheimer's disease (AD) occurring before 65 years of age is commonly
referred to as early-onset Alzheimer's disease (EOAD) and constitutes~ 5–6% of all AD …

Both clinical diagnosis and neuropathological diagnosis are commonly used in literature to
categorize individuals as Alzheimer's disease (AD) or non‐AD in omics analyses. Whether …

Alzheimer's disease (AD) is a neurodegenerative disease. Mitochondrial energy metabolism
and p70 ribosomal protein S6 kinase (p70S6K) play significant roles in AD pathology …

阿尔茨海默病(Alzheimer'sdisease, AD) 是最常见的神经退行性疾病. 大量证据表明,
遗传因素在AD 的发病机制中起重要作用. 2 型髓系细胞触发受体(triggering receptor expressed …

Methods Employing the robust tools of R-language, we dissected vast RNA sequence
datasets comprising numerous samples and thousands of genes, pinpointing potential …

Background Mutations in PSEN1, PSEN2, and APP can lead to Alzheimer's disease (AD)
with an early age at onset (AAO) and hallmark progressive cognitive decline. These …